Fig. 5
From: A new polysaccharide platform constructs self-adjuvant nanovaccines to enhance immune responses
The biocompatibility and biosafety of PRBS. a The viability of macrophages treated with 100 μg/mL and 200 μg/mL PRBS at 0, 24, 48 h incubation. b The weight of mice in control group (normal mice) and PRBS-treated group (400 μg/kg PRBS). c The concentration of hemoglobin, the number of platelet and red blood cells in control group (normal mice) and PRBS-treated group (400 μg/kg PRBS). d The concentrations of albumin, urea, uric acid, alanine aminotransferase, aspartate transaminase, creatinine and amylase in mouse serum samples from control group (normal mice) and PRBS-treated group (400 μg/kg PRBS). e The immunohistochemical images (H&E staining) of heart, liver, spleen, lung and kidney from control group (normal mice) and PRBS-treated group (400 μg/kg PRBS). Scale bar = 200 μm